TRAXFirst Tracks Biotherapeutics, Inc.
$16.37
$16.37
$15.3252 weeks$47.80
Price
End-of-day closes, not the intraday tick.
The five questions
1 of 5 availableOnly one of the five can be answered for TRAX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?not enough filed
P/En/a
Market value$1.12B
1 yearn/a
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 11, 2026, a quarter after the last one.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 12, 2026First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 22, 2026On June 15, 2026, First Tracks Biotherapeutics, Inc. (the “Company”), entered into a Sublease Agreement (the “Sublease”) with AnaptysBio, Inc., a Delaware corporation (“AnaptysBio”), pursuant to which AnaptysBio agreed to sublease to the Company approximately 45,057 rentable square feet of space located at 10770 …Material agreement entered · Form 8-K
- May 14, 2026First Tracks Biotherapeutics Announces First Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Biotechnology
The closest names by size in the same industry